Zobrazeno 1 - 10
of 267
pro vyhledávání: '"Toru Kumagai"'
Autor:
Yukio Kadokawa, Satoko Inoue, Akitoshi Tatsumi, Mayako Uchida, Keiko Fujita, Mari Takagi, Takako Inoue, Shuichi Ohe, Yasutomo Nakai, Tomoyuki Otsuka, Yutaro Abe, Tasuku Nakabori, Taiki Isei, Toru Kumagai, Kazuo Nishimura, Kazuyoshi Ohkawa
Publikováno v:
JGH Open, Vol 7, Iss 2, Pp 87-97 (2023)
Abstract Background and Aim To investigate the outcomes in eight Japanese patients with cancer treated with mycophenolate mofetil (MMF) and corticosteroids for immune checkpoint inhibitor treatment‐induced severe immune‐related hepatitis (ir‐he
Externí odkaz:
https://doaj.org/article/20fb7ec5c2094174a292bc9a4c635f1e
Autor:
Kei Kunimasa, Kazumi Nishino, Yoshiharu Sato, Masahide Mori, Shoichi Ihara, Hidekazu Suzuki, Izumi Nagatomo, Toru Kumagai, Toshitaka Morishima, Fumio Imamura
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-12 (2022)
Abstract Circulating tumor DNA (ctDNA)-based next-generation sequencing (NGS) is a complementary and alternative test to tissue-based NGS. We performed NGS analysis of ctDNA samples collected from patients with EGFR-mutated non-small cell lung cancer
Externí odkaz:
https://doaj.org/article/d8b2c1c79b144483bd271dabdd44fdc3
Autor:
Kei Kunimasa, Shingo Matsumoto, Kazumi Nishino, Keiichiro Honma, Noboru Maeda, Hanako Kuhara, Motohiro Tamiya, Takako Inoue, Takahisa Kawamura, Toru Kimura, Tomohiro Maniwa, Jiro Okami, Koichi Goto, Toru Kumagai
Publikováno v:
Cancer Medicine, Vol 11, Iss 14, Pp 2744-2754 (2022)
Abstract Introduction Success of next generation sequencing (NGS) analysis is becoming indispensable in the treatment of advanced lung cancer. However, the advantages and disadvantages of each sampling method in the NGS analysis have not yet been cla
Externí odkaz:
https://doaj.org/article/978e7bbf0f754bd9ad62e1525b8d6435
Autor:
Tatsuya Nishikawa, MD, PhD, Motohiro Tamiya, MD, PhD, Keiko Ohta-Ogo, MD, PhD, Yoshihiko Ikeda, MD, PhD, Kinta Hatakeyama, MD, PhD, Keiichiro Honma, MD, PhD, Taku Yasui, MD, PhD, Wataru Shioyama, MD, PhD, Toru Oka, MD, PhD, Takako Inoue, MD, PhD, Toru Kumagai, MD, PhD, Masashi Fujita, MD, PhD
Publikováno v:
CJC Open, Vol 4, Iss 7, Pp 651-655 (2022)
Immune checkpoint inhibitor (ICI)-related myocarditis has been reported to appear in the early phase after ICI initiation. Herein, we report the case of a 78-year-old man with non-small cell lung cancer. Pembrolizumab was introduced as first-line the
Externí odkaz:
https://doaj.org/article/01237cec898f4be6bbee853f81fc9bbc
Autor:
Hidetoshi Hayashi, MD, PhD, Shunsuke Teraoka, MD, Yasushi Goto, MD, PhD, Toru Kumagai, MD, PhD, Makoto Nishio, MD, PhD, Shunichi Sugawara, MD, PhD, Satoshi Oizumi, MD, PhD, Masakazu Matsumura, MS, Masayuki Okura, PhD, Gerson Peltz, MD, MPH, Terufumi Kato, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 4, Pp 100471- (2023)
Introduction: Lorlatinib, a third-generation ALK inhibitor, was found to have improved efficacy versus crizotinib in patients with previously untreated, advanced ALK-positive NSCLC in the ongoing, global, randomized, phase 3 CROWN study. Methods: The
Externí odkaz:
https://doaj.org/article/f668029f82e34de79779c4090f8033cc
Autor:
Kei Kunimasa, Takahisa Kawamura, Motohiro Tamiya, Takako Inoue, Hanako Kuhara, Kazumi Nishino, Toru Kumagai
Publikováno v:
Thoracic Cancer, Vol 12, Iss 24, Pp 3426-3428 (2021)
Abstract In May 2020 and February 2021, capmatinib and tepotinib, respectively were approved by the Food and Drug Administration (FDA) for the treatment of metastatic non‐small cell lung carcinoma harboring mesenchymal‐epithelial transition (MET)
Externí odkaz:
https://doaj.org/article/4c313458aa0f4eef80997d324186fc5c
Autor:
Hayato Kawachi, MD, Motohiro Tamiya, MD, Yoshihiko Taniguchi, MD, Toshihide Yokoyama, MD, Shinya Yokoe, MD, Yuko Oya, MD, PhD, Mihoko Imaji, MD, Fukuko Okabe, MD, Masaki Kanazu, MD, Yoshihiko Sakata, MD, Shinya Uematsu, MD, Satoshi Tanaka, MD, Daisuke Arai, MD, PhD, Go Saito, MD, Hiroshi Kobe, MD, Eisaku Miyauchi, MD, PhD, Asuka Okada, MD, PhD, Satoshi Hara, MD, Toru Kumagai, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 7, Pp 100355- (2022)
Introduction: Malignant pleural effusion (MPE) is associated with poor treatment outcome in patients with NSCLC receiving immune checkpoint inhibitors (ICIs). ICIs and chemotherapy (ICI/Chemo) combination therapy is currently the standard therapy for
Externí odkaz:
https://doaj.org/article/a1964b63c30847029c4b83600c97ce97
Autor:
Motohiro Tamiya, Akihiro Tamiya, Norio Okamoto, Yoshihiko Taniguchi, Kazumi Nishino, Shinji Atagi, Tomonori Hirashima, Fumio Imamura, Toru Kumagai, Hidekazu Suzuki
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
Abstract The most frequent mechanism of resistance after 1st/2nd-generation (G) epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) is secondary point mutation Thr790Met (T790M) in EGFR. Afatinib followed by osimertinib (Afa gro
Externí odkaz:
https://doaj.org/article/971c6d6d531f455c899f4cb3858135b3
Autor:
Kazutaka Hosoya, Daichi Fujimoto, Takeshi Morimoto, Toru Kumagai, Akihiro Tamiya, Yoshihiko Taniguchi, Toshihide Yokoyama, Tadashi Ishida, Hirotaka Matsumoto, Katsuya Hirano, Ryota Kominami, Keisuke Tomii, Hidekazu Suzuki, Tomonori Hirashima, Satoshi Tanaka, Junji Uchida, Mitsunori Morita, Masaki Kanazu, Masahide Mori, Kenji Nagata, Ikue Fukuda, Motohiro Tamiya
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
Abstract Background Despite the wide-spread use of immune checkpoint inhibitors (ICIs) in cancer chemotherapy, reports on patients developing acquired resistance (AR) to ICI therapy are scarce. Therefore, we first investigated the characteristics ass
Externí odkaz:
https://doaj.org/article/735dc8f05e034b26bae5069dc3ac3af2
Autor:
Kentaro Masuhiro, Motohiro Tamiya, Kosuke Fujimoto, Shohei Koyama, Yujiro Naito, Akio Osa, Takashi Hirai, Hidekazu Suzuki, Norio Okamoto, Takayuki Shiroyama, Kazumi Nishino, Yuichi Adachi, Takuro Nii, Yumi Kinugasa-Katayama, Akiko Kajihara, Takayoshi Morita, Seiya Imoto, Satoshi Uematsu, Takuma Irie, Daisuke Okuzaki, Taiki Aoshi, Yoshito Takeda, Toru Kumagai, Tomonori Hirashima, Atsushi Kumanogoh
Publikováno v:
JCI Insight, Vol 7, Iss 9 (2022)
Bronchoalveolar lavage is commonly performed to assess inflammation and identify responsible pathogens in lung diseases. Findings from bronchoalveolar lavage might be used to evaluate the immune profile of the lung tumor microenvironment (TME). To in
Externí odkaz:
https://doaj.org/article/641f4d15feef4e44af06979b1005ab6a